Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after ...

Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Arvinas (NASDAQ:ARVN – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a research report issued on Tuesday, Marketbeat Ratings ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Lifetime Brands Inc (LCUT) is expected to report $0.40 for 4Q. Lipocine Inc (LPCN) is expected to report $-0.40 for 4Q. Medical Facilities Corp (DR.T) is expected to report $0.41 for 4Q. Mondee ...

Susquehanna cut Teradyne, Inc. TER price target from $165 to $155. Susquehanna analyst Mehdi Hosseini maintained a Positive ...